{"id":"eltrombopag-pfos","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Thrombotic events"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL3989691","moleculeType":"Small molecule","molecularWeight":"564.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eltrombopag mimics the action of thrombopoietin, a natural hormone that regulates platelet production. By activating TPO receptors on bone marrow megakaryocytes, it promotes their proliferation and differentiation, leading to increased platelet output. This mechanism is used to treat conditions characterized by low platelet counts (thrombocytopenia).","oneSentence":"Eltrombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on megakaryocytes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:42.061Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Immune thrombocytopenia (ITP)"},{"name":"Thrombocytopenia associated with chronic hepatitis C"}]},"trialDetails":[{"nctId":"NCT07476846","phase":"NA","title":"rhTPO Dose Escalation vs Eltrombopag Switch in ITP","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":112},{"nctId":"NCT07189910","phase":"PHASE4","title":"Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-12-01","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":150},{"nctId":"NCT07001397","phase":"PHASE3","title":"Study on the Short-term Efficacy and Safety of Recombinant Human Thrombopoietin Combined With Immunosuppressant Sequential Eltrombopag Ethanolamine Dry Suspension in the Treatment of SAA/TD-NSAA","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-06-23","conditions":"Aplastic Anemias","enrollment":70},{"nctId":"NCT03025698","phase":"PHASE2","title":"A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-30","conditions":"Aplastic Anemia","enrollment":51},{"nctId":"NCT01957176","phase":"PHASE4","title":"A Rollover Study to Provide Continued Treatment With Eltrombopag","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-10-15","conditions":"Thrombocytopaenia","enrollment":22},{"nctId":"NCT02201290","phase":"PHASE3","title":"A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-06-18","conditions":"Purpura, Thrombocytopenic, Idiopathic","enrollment":9},{"nctId":"NCT00909363","phase":"PHASE2","title":"Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2009-06","conditions":"Wiskott-Aldrich Syndrome, Thrombocytopenia, Bleeding","enrollment":24},{"nctId":"NCT01072162","phase":"PHASE1","title":"Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-01-12","conditions":"Purpura, Thrombocytopaenic, Idiopathic","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Eltrombopag PfOS","genericName":"Eltrombopag PfOS","companyName":"Institute of Hematology & Blood Diseases Hospital, China","companyId":"institute-of-hematology-blood-diseases-hospital-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eltrombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on megakaryocytes. Used for Immune thrombocytopenia (ITP), Thrombocytopenia associated with chronic hepatitis C.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}